Abivax S.A.(ABVX)
POST5.790.000.00%16:00 EDT
5.79-0.26-4.30%
Market data delayed 15 minutes
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
No ContentCompany Profile
Company NameAbivax S.A.MarketNASDAQEstablishment Date- -Employees- -Office Location- -WebsiteZip Code- -Phone- -Fax- -IntroductionABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.- 03-24Form S-8 - Securities to be offered to employees in employee benefit plansEmployee Stock OwnershipForm S-8 - Securities to be offered to employees in employee benefit plans
- 03-24Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]Annual ReportForm 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-11-25Form CORRESP - CorrespondenceCorrespondenceForm CORRESP - Correspondence
- 2024-11-14Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]Beneficial Ownership ChangeForm SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 2024-04-19Form SC 13G - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeForm SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2024-04-05Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]Annual ReportForm 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-02-14Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]Beneficial Ownership ChangeForm SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2023-11-22Form SC 13G - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeForm SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-10-30Form SC 13G - Statement of acquisition of beneficial ownership by individualsBeneficial Ownership ChangeForm SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2023-10-30Form SC 13D - General statement of acquisition of beneficial ownershipBeneficial Ownership ChangeForm SC 13D - General statement of acquisition of beneficial ownership
- 2023-10-20Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses[Supp]Public ProspectusForm FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 2023-10-18Form CORRESP - CorrespondenceCorrespondenceForm CORRESP - Correspondence
- 2023-10-18Form CORRESP - CorrespondenceCorrespondenceForm CORRESP - Correspondence
- 2023-10-18Form CORRESP - CorrespondenceCorrespondenceForm CORRESP - Correspondence
- 2023-10-18Form F-1/A - Registration statement for certain foreign private issuers: [Amend][Amend]Public ProspectusForm F-1/A - Registration statement for certain foreign private issuers: [Amend]
- 1D
- 5D
- Day
- Week
- Month
Loading ...
High
6.00
Open
6.00
Volume%
0.54
Low
5.73
Close
6.05
T/O Rate
0.33%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial